🇸🇪 Sweden
01
Medical cannabis in the form of oil or flowers is currently only available through a rigorous licence approval process where specialist doctors must submit an application for their patient, reviewed and granted by the Swedish Medical Products Agency.
02
A prescriber must provide evidence within the application that the unregistered medical cannabis product is beneficial for the well-being of its patient and that other treatment methods have been exhausted.
03
If a licence is granted, the Swedish Medical Products Agency, provides a prescription for three months during which the patient’s effect on the treatment is evaluated, and if the situation is beneficial for the patient, the prescriber may apply for an annual licence. In the last years, the number of medical cannabis licences have been increasing with projected 2025 sales figures estimated at €XXX (click here for more information about premium data packages, including market sizing forecasts).
04
In 2024, the Karolinska Institute, in collaboration with Cura Leaf’s Sapphire Clinics, launched a national observational study on the treatment of cannabis based preparations, collecting data to evaluate the treatment effects of prescribed cannabis-based medicines.